Table 1.
Criteria of RISS, DSS, and DS Plus staging systems.
| RISS [6] | DSS [4] | DS Plus [8] | |
|---|---|---|---|
| Stage I | ISS stage I (serum albumin ≥3.5 and serum β2-microglobulin <3.5), normal LDH levels, and no high-risk cytogenetic abnormalities | All of the following: hemoglobin value >10 g/dL; serum calcium value normal or ≤10.5 mg/dL; bone X-ray shows normal bone structure or solitary bone plasmacytoma only; and low M-component production rates (IgG < 5 g/dL, IgA < 3 g/dL, and Bence Jones protein < 4 g/24 h) | Stage IA, smoldering or indolent: single plasmacytoma and/or limited disease at imaging Stage IB: 0–4 focal lesions or mild diffuse disease |
|
| |||
| Stage II | Neither stage I nor stage III | Neither stage I nor stage III | 5–20 focal lesions or moderate diffuse disease |
|
| |||
| Stage III | ISS stage III (serum β2-microglobulin >5.5 mg/L) and either elevated LDH levels or high-risk cytogenetic abnormalities | One or more of the following: hemoglobin value <8.5 g/dL; serum calcium value <12 mg/dL; advanced lytic bone lesions; and high M-component production rates (IgG > 7 g/dL, IgA > 5 g/dL, or Bence Jones protein >12 g/24 h) | >20 focal lesions or severe diffuse disease |
|
| |||
| Subgroup A | — | Relatively normal renal function: serum creatinine value <2.0 mg/dL | Serum creatinine level <2.0 mg/dL and no EMD |
|
| |||
| Subgroup B | — | Abnormal renal function: serum creatinine value ≥2.0 mg/dL | Serum creatinine level >2.0 mg/dL and/or the presence of EMD |